Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Share-based Compensation: 2012-2024

Historic Share-based Compensation for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $27.8 million.

  • Coherus Oncology's Share-based Compensation fell 50.66% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year decrease of 36.16%. This contributed to the annual value of $27.8 million for FY2024, which is 35.51% down from last year.
  • Latest data reveals that Coherus Oncology reported Share-based Compensation of $27.8 million as of FY2024, which was down 35.51% from $43.1 million recorded in FY2023.
  • Coherus Oncology's 5-year Share-based Compensation high stood at $51.4 million for FY2021, and its period low was $27.8 million during FY2024.
  • Moreover, its 3-year median value for Share-based Compensation was $43.1 million (2023), whereas its average is $40.5 million.
  • Per our database at Business Quant, Coherus Oncology's Share-based Compensation soared by 34.60% in 2021 and then slumped by 35.51% in 2024.
  • Coherus Oncology's Share-based Compensation (Yearly) stood at $38.2 million in 2020, then soared by 34.60% to $51.4 million in 2021, then decreased by 1.22% to $50.7 million in 2022, then declined by 15.03% to $43.1 million in 2023, then slumped by 35.51% to $27.8 million in 2024.